Adiponectin - stratification biomarker in diastolic cardiac dysfunction

J Enzyme Inhib Med Chem. 2023 Dec;38(1):2171030. doi: 10.1080/14756366.2023.2171030.

Abstract

This study does not propose to elucidate how adiponectin secretion is regulated, but how its adiponectin concentration is an indicator of heart disease. About adiponectin, it is not known whether it is functionally an enzyme, or very likely a cytokine/chemokine/hormone, secreted by fat cells/adipocytes in the abdomen. Abdominal fat secretes 67 hormones, and all of which cause disease. For example, adiponectin generates diabetes and ischaemic heart disease via dyslipidemia. Based on clinical symptoms, electrocardiographic and echocardiographic parameters, a group of 208 patients with diastolic cardiac dysfunction with or without preserved systolic function, developed on a background of painful chronic ischaemic heart disease, stable angina on exertion, was constituted. The serum levels of adiponectin, total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides were measured. Using the identified values, it was appreciated whether adiponectin correlates with the type of any of the two conditions, so that it can be recognised as a diagnostic and risk stratification marker.

Keywords: Adiponectin; biomarker; coronary artery disease (CAD); diastolic dysfunction (DD); left ventricular ejection fraction (LVEF); preserved systolic function (PRESYF).

MeSH terms

  • Adiponectin
  • Biomarkers
  • Echocardiography
  • Heart Diseases*
  • Humans
  • Myocardial Ischemia*

Substances

  • Adiponectin
  • Biomarkers
  • ADIPOQ protein, human

Grant support

The author(s) reported there is no funding associated with the work featured in this article.